Literature DB >> 8649352

Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance.

P Chiba1, G Ecker, D Schmid, J Drach, B Tell, S Goldenberg, V Gekeler.   

Abstract

The sodium channel blocker propafenone and a series of analogs have been identified as effective modulators of P-glyco-protein-mediated multidrug resistance in human tumor cells. A series of closely related structural homologues showed a highly significant correlation between lipophilicity and pharmacological effect. Reduction of the carbonyl group as well as conversion to a methylether led to a remarkable decrease in activity, whereby lipophilicity lost its predictive character as the main determinant for modulator potency. Similarly, the relative positioning of the acyl- and propanolamine side chains also influences activity, so the distance between carbonyl group and nitrogen atom seems important.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649352

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  MCASE study of the multidrug resistance reversal activity of propafenone analogs.

Authors:  Gilles Klopman; Hao Zhu; Gerhard Ecker; Peter Chiba
Journal:  J Comput Aided Mol Des       Date:  2003 May-Jun       Impact factor: 3.686

Review 2.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein.

Authors:  Zahida Parveen; Thomas Stockner; Caterina Bentele; Sandra Pferschy; Martin Kraupp; Michael Freissmuth; Gerhard F Ecker; Peter Chiba
Journal:  Mol Pharmacol       Date:  2010-12-21       Impact factor: 4.436

Review 4.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Menyhárt B Sárosi; Cristina M Daniel; Kebreab Ghebreselasie; Matthias S Scholz; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-10-15       Impact factor: 3.466

6.  Surface plasmon resonance biosensor combined with lentiviral particle stabilization strategy for rapid and specific screening of P-Glycoprotein ligands.

Authors:  Yuhong Cao; Yan Cao; Yiwei Shi; Ying Cai; Langdong Chen; Dongyao Wang; Yue Liu; Xiaofei Chen; Zhenyu Zhu; Zhanying Hong; Yifeng Chai
Journal:  Anal Bioanal Chem       Date:  2021-02-02       Impact factor: 4.142

7.  Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.

Authors:  Iouri Bachmakov; Sabine Rekersbrink; Ute Hofmann; Michel Eichelbaum; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-15       Impact factor: 3.000

Review 8.  Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.

Authors:  Dhananjay Pal; Deep Kwatra; Mukul Minocha; Durga K Paturi; Balasubrahmanyam Budda; Ashim K Mitra
Journal:  Life Sci       Date:  2010-11-01       Impact factor: 5.037

9.  Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113.

Authors:  Severin Mairinger; Thomas Wanek; Claudia Kuntner; Yaprak Doenmez; Sabine Strommer; Johann Stanek; Elena Capparelli; Peter Chiba; Markus Müller; Nicola A Colabufo; Oliver Langer
Journal:  Nucl Med Biol       Date:  2012-09-13       Impact factor: 2.408

10.  Trapping and dissociation of propafenone derivatives in HERG channels.

Authors:  A Windisch; En Timin; T Schwarz; D Stork-Riedler; T Erker; Gf Ecker; S Hering
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.